ZZPZH(SH:600436) Sou Hu Cai Jing·2026-01-29 09:49Core Viewpoint - The Chinese medicine sector is experiencing a rebound, with the Chinese Medicine ETF (560080) showing significant inflows and a notable increase in trading volume, indicating renewed investor interest [1][5]. Group 1: Market Performance - The Chinese Medicine ETF (560080) rose by 1.34% with a trading volume of nearly 100 million yuan, reflecting a 34% increase compared to the previous period [1]. - Over the past three days, the ETF has attracted approximately 100 million yuan in investments [1]. - Key constituent stocks of the ETF, such as Pizhou Pharmaceutical, have shown strong performance, with Pizhou rising nearly 7% after a nine-day decline [5]. Group 2: Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the Chinese Medicine ETF is 24.23, which is below 83.95% of the time since its inception in May 2015, indicating attractive valuation [3]. - The index's valuation percentile is at 16.05%, suggesting a favorable price-performance ratio for investors [3]. Group 3: Future Outlook - The Chinese medicine sector is expected to recover in 2026 after a weak performance in 2025, driven by inventory digestion and an increase in flu incidence, which may boost demand for OTC products [7]. - Companies with strong brand power and effective inventory management are likely to benefit from the anticipated recovery in the sector [8]. - The adjustment of the essential drug list is expected to progress in 2026, potentially enhancing the accessibility of traditional Chinese medicine [8]. Group 4: Investment Recommendations - Investors are advised to focus on high-quality assets with low valuations in the Chinese medicine sector, particularly those that can effectively manage inventory and have strong brand recognition [8][9]. - The performance of companies that successfully integrate both hospital and outpatient markets is highlighted as a key factor for future growth [8].